skip to main content

HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials

Volk Je ; Hessol Na ; Gray Ge ; Kublin Jg ; Churchyard G ; Mlisana K ; Nchabeleng M ; Buchbinder Sp ; Bekker L

Retrovirology, 01 September 2012, Vol.9(Suppl 2), p.P131 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
  • Título:
    HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials
  • Autor: Volk Je ; Hessol Na ; Gray Ge ; Kublin Jg ; Churchyard G ; Mlisana K ; Nchabeleng M ; Buchbinder Sp ; Bekker L
  • Assuntos: Biology
  • É parte de: Retrovirology, 01 September 2012, Vol.9(Suppl 2), p.P131
  • Descrição: Worldwide, many adolescents, especially women, acquire HIV before age 18. Yet to date, no HIV vaccine trials have enrolled adolescents. Reasons for excluding adolescents from these trials include regulations protecting vulnerable subjects and concerns regarding informed consent, social harms, adverse events, and loss to follow-up.
  • Idioma: Inglês

Buscando em bases de dados remotas. Favor aguardar.